TABLE 2.
Treatment regimens before detection of macrolide-resistant M. abscessus subsp. abscessus lung diseasea,b
| Treatment regimen | Value | Duration of macrolide exposure, mo |
|---|---|---|
| Antibiotic therapy for M. abscessus subsp. abscessus lung disease | ||
| Macrolide + i.v. antibioticsc ± FQ ± DOX ± CFZ | 10 (77) | 25.5 (9.3–45.0) |
| Antibiotic therapy for other NTM lung disease | ||
| Macrolide + RIF + EMBd | 2 (15) | 17.0 (NA) |
| Macrolide + i.v. antibioticse | 1 (8) | 11.0 (NA) |
| Total | 13 (100) | 19.0 (10.5–42.5) |
a
The total number of patients in the study was 13. Abbreviations: i.v., intravenous; FQ, fluoroquinolone; DOX, doxycycline; CFZ, clofazimine; NTM, nontuberculous mycobacteria; RIF, rifampin; EMB, ethambutol; NA, not available.
b
Data are presented as number (percent) or as median (interquartile range).
c
Intravenous antibiotics included amikacin and cefoxitin (or imipenem).
d
Combination antibiotic therapy for M. avium complex lung disease.
e
Combination antibiotic therapy for M. abscessus subsp. massiliense lung disease.